Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
_256_384.jpg)
GenWorks Health Introduces Braster Pro for breast screening & EVA for cervical screening in rural areas & communities
Our collaboration with MediSage to present 'Current Approaches to Uro-Oncology' embodies a crucial stride towards comprehensive cancer care
Marks the World Head & Neck Cancer Day at the OCTF Conference
OncoVeryx-F, a proprietary test developed by PredOmix, is set to transform early-stage cancer detection
It provides doctors with three indicators: identification of the bone, confirmation of device insertion into the bone, and notification in case of perforation through the opposite end of the bone
To bring quality cancer treatment closer to patients, India’s leading MedTech brand is joining forces with the unique technology-led platform
APAC region contributed around 50% of the in-vitro diagnostics market in 2022
Timely screening and accurate detection through precision diagnostics, targeted therapy, risk reducing surgeries, and comprehensive multimodality treatment options have resulted in improving survival rates and quality of life in cancer patients in India
Singapore presents great opportunities for the adoption of technology in healthcare and is open for investments
Subscribe To Our Newsletter & Stay Updated
